3SBIO Aktie

 

There was HKD2.1 billion, HKD2 billion and HKD1.4 billion Southbound Trading net inflow to BABA-W (09988.HK), MEITUAN-W (03690.HK) and HORIZONROBOT-W (09660.HK).There was HKD576.5 million Southbound Trading net outflow from 3SBIO (01530.HK). For Southbound Trading of Shanghai-Hong Kong Stock Connect, BABA-W (09988.HK) was the mo......

At close, HSI rose 359 pts or 1.4% to 25,417. HSTI rose 108 pts or 1.9% to 5,687. HSCEI gained 120 pts or 1.3% to 9,057. Market turnover reached $299.95 billion.Active Heavyweights:TENCENT (00700.HK) closed at $605.5, up 2.2%MEITUAN (03690.HK) closed at $103, up 1.6%BABA (09988.HK) closed at $131.8, up 1.5%XIAOMI (01810.HK) clos......

3SBIO (01530.HK)'s 1H25 revenue fell 0.8% YoY to RMB4.356 billion, while net profit attributable to shareholders increased by 24.6% YoY to RMB1.358 billion, according to CICC's research report. Adjusted net profit grew by 2.1% YoY to RMB1.136 billion, in line with market consensus.Considering the revenue recognition from......

MSCI announced changes in constituents for the MSCI China Index adding 14 stocks and removing 17 stocks. These changes will take effect after the market closes on 26 August.Newly included Hong Kong-listed stocks include 3 3SBIO (01530.HK), CITIC FAMC (02799.HK), LAOPU GOLD (06181.HK), MEITU (01357.HK), NETEASE MUSIC (09899.HK), ......

HSBC Global Research released a report listing the H-shares most favored by domestic active mutual funds in 2Q25 as follows:Stock|Industry|Net Buy (RMB)INNOVENT BIO (01801.HK)|Healthcare|5 billion3 3SBIO (01530.HK)|Healthcare|4.9 billionJD HEALTH (06618.HK)|Healthcare|2.9 billionCSPC PHARMA (01093.HK)|Healthcare|1.9 billionHKEX ......

Pfizer and 3SBio have completed a licensing agreement that grants the US pharmaceutical giant worldwide rights to sell the Hong Kong-listed firm's cancer drug, marking the largest deal ever for a single drug in China's biotech industry. First announced in May, the deal will see 3SBio – based in Shenyang, capital of northeastern Liaoning province – receive a US$1.25 billion upfront payment from Pfizer for the exclusive right to sell its cancer drug, SSGJ-707, outside China. Under the terms of......

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) Thursday said it has completed the licensing agreement with 3SBio, Inc. for exclusive rights to develop and sell 3SBio's SSGJ-707.As per the deal, 3SBio......

Stock│Mkt value of holdings in 2Q25 (RMB)│ Change in mkt value of holdings from 1Q to 2Q (RMB)INNOVENT BIO (01801.HK)│15.531 billion │+10.518 billion 3 3SBIO (01530.HK)│8.52 billion │+7.189 billion POP MART (09992.HK)│15.742 billion │+6.962 billion CSPC PHARMA (01093.HK)│3.89......

UBS report listed the Buy-rated HK-listed stocks with highest UBS earnings upside above consensus estimate:Shares│UBS vs consensus' comprehensive profit forecast differences for companies in 2025 and 2026CANSINOBIO (06185.HK)│97%CSPC PHARMA (01093.HK)│60%3SBIO (01530.HK)│42%CARSGEN-B (02171.HK)│......

Folgendes Instrument wird heute EX-Kapitalmassnahme gehandelt. Aus technischen Gruenden wird der EX-Indikator heute nicht angezeigt. The following instrument is traded ex capital adjustment today. Due to technical reasons the EX-indicator will not be displayed today. ISIN Short Code Name KYG8875G1029 83B 3SBio Inc....

Das Instrument 83B KYG8875G1029 3SBIO INC. DL -,00001 EQUITY wird cum Dividende/Zinsen gehandelt am 18.07.2025 und ex Dividende/Zinsen am 21.07.2025 The instrument 83B KYG8875G1029 3SBIO INC. DL -,00001 EQUITY has its pre-dividend/interest day on 18.07.2025 and its ex-dividend/interest day on 21.07.2025...

At close, HSI rose 63 pts or 0.3% to 24,203. HSTI rose 35 pts or 0.7% to 5,283. HSCEI gained 45 pts or 0.5% to 8,732. Market turnover reached $210.36 billion.Active Heavyweights:BABA (09988.HK) closed at $106.1, up 1%MEITUAN (03690.HK) closed at $120.9, up 0.8%CCB (00939.HK) closed at $8.41, up 0.7%TENCENT (00700.HK) closed at $......

UBS released a research report initiating coverage on 3SBIO (01530.HK), with rating at Buy and a target price of $30.3SBIO's core products target hematology and autoimmune diseases, according to the report. The broker believed that the recent record-breaking US$6.15 billion out-licensing agreement with Pfizer (PFE.US) for SS......

The MSCI China Health Care Index has already snowballed by 31.7% YTD, outpacing the MSCI China Index by 18.2%, according to a report from CMBI. Due to the market's high expectations for the frequency and scale of overseas transactions, it is expected that the industry may still face some pullback pressure in the short term.C......

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study....

3SBIO (01530.HK) will grant Pfizer exclusive rights for the development, production and commercialization of its PD-1/VEGF bispecific antibody (SSGJ-707) outside China, CICC published a research report saying. Pfizer will have the option for commercialization in the Chinese market. Therefore, the broker maintained its 2025/ 2026......

There was HKD656 million, HKD587 million and HKD268.3 million Southbound Trading net inflow to MEITUAN-W (03690.HK), CNOOC (00883.HK) and 3SBIO (01530.HK).There was HKD1.3 billion, HKD897.7 million and HKD447.3 million Southbound Trading net outflow from TENCENT (00700.HK), BABA-W (09988.HK) and XIAOMI-W (01810.HK).For Southboun......

Pfizer will produce the drug, which targets lung and colorectal cancers, in the US and take a US$100 million stake in China's 3SBio....

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

3SBIO (01530.HK) signed the largest single asset transaction in China's biopharmaceutical industry with Pfizer, involving an upfront payment of US$1.25 billion and a total scale of US$6 billion, according to CMSI's research report.CMSI had previously alerted investors about the licensing transfers of PD-1xVEGF and TL1A, ......